Back to Results
First PageMeta Content
Oncology / Orphan drugs / Myelodysplastic syndrome / Syndromes / Azacitidine / Decitabine / Cyclacel / Medicine / Nucleosides / Triazines


June 14, 2013 Astex Pharmaceuticals Announces Presentation of Updated Results of SGI[removed]Study in Patients With Intermediate or High Risk Relapsed or Refractory Myelodysplastic Syndromes at the European Hematology As
Add to Reading List

Open Document

File Size: 24,02 KB

Share Result on Facebook

City

DUBLIN / New Orleans / Stockholm / /

Company

Astex Pharmaceuticals Inc. / Astex Pharmaceuticals Astex Pharmaceuticals / /

Country

Sweden / /

Event

FDA Phase / /

IndustryTerm

pharmaceutical / /

MedicalCondition

Refractory Myelodysplastic Syndromes / cancer / chronic myelomonocytic leukemia / silenced tumor / pain / /

MedicalTreatment

chemotherapy / /

Organization

Congress / American Society of Hematology / European Hematology Association / /

Person

James S.J. Manuso / /

Position

chief executive officer and chairman / /

Product

DACOGEN / SGI-110 / SGI / SGI110-01 / MDS / /

ProvinceOrState

Hawaii / California / /

Technology

gene expression / chemotherapy / /

URL

http /

SocialTag